Smith & Nephew plc vs Tapestry, Inc. — how do they compare? Smith & Nephew plc trades at $27.72 (market cap $11.63B), while Tapestry, Inc. trades at $113.97 (market cap $23.44B). The key difference: Tapestry, Inc. is far larger — about 2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| SNN | TPR | |
|---|---|---|
Market Cap | $11.63B | $23.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $38.53 | $164.78 |
52-Week Low | $27.80 | $98.81 |
Enterprise Value | $14.66B | $26.25B |
Dividend Yield | 2.85% | 1.57% |
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
TPR (Tapestry Inc.) is trading at $117.58, down 3.73% in the last session, with a bearish technical signal despite bullish oscillators. The company shows strong profitability with 77.82% gross margins and 19.09% net income margin, though 2025 net income declined significantly. Recent earnings have consistently beaten estimates, and analyst consensus remains strongly bullish with a $182.44 price target representing 55% upside potential.
The outlook remains positive with international growth accelerating in China and Europe, supported by a direct-to-consumer model. Key risks include Kate Spade execution challenges, tariff pressures, and premium valuation. Institutional buying activity remains strong, with BlackRock acquiring a $2.6 billion position in Q2 2026, supporting the bullish analyst sentiment.
Trailing returns across standard periods
Latest headlines on both assets
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →